ATE490964T1 - Pyrrolopyridazin-verbindungen und verwendungsverfahren dafür zur behandlung von proliferativen erkrankungen - Google Patents

Pyrrolopyridazin-verbindungen und verwendungsverfahren dafür zur behandlung von proliferativen erkrankungen

Info

Publication number
ATE490964T1
ATE490964T1 AT03719500T AT03719500T ATE490964T1 AT E490964 T1 ATE490964 T1 AT E490964T1 AT 03719500 T AT03719500 T AT 03719500T AT 03719500 T AT03719500 T AT 03719500T AT E490964 T1 ATE490964 T1 AT E490964T1
Authority
AT
Austria
Prior art keywords
methods
proliferative diseases
treating proliferative
pyrrolopyridazine compounds
pyrrolopyridazine
Prior art date
Application number
AT03719500T
Other languages
English (en)
Inventor
Mark Salvati
Stephanie Barbosa
Zhong Chen
John Hunt
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE490964T1 publication Critical patent/ATE490964T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
AT03719500T 2002-03-28 2003-03-26 Pyrrolopyridazin-verbindungen und verwendungsverfahren dafür zur behandlung von proliferativen erkrankungen ATE490964T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36824902P 2002-03-28 2002-03-28
US40211802P 2002-08-08 2002-08-08
PCT/US2003/009550 WO2003082208A2 (en) 2002-03-28 2003-03-26 Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders

Publications (1)

Publication Number Publication Date
ATE490964T1 true ATE490964T1 (de) 2010-12-15

Family

ID=28678223

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03719500T ATE490964T1 (de) 2002-03-28 2003-03-26 Pyrrolopyridazin-verbindungen und verwendungsverfahren dafür zur behandlung von proliferativen erkrankungen

Country Status (12)

Country Link
US (2) US6900208B2 (de)
EP (1) EP1578351B1 (de)
JP (1) JP4589005B2 (de)
AR (1) AR039189A1 (de)
AT (1) ATE490964T1 (de)
AU (1) AU2003223380A1 (de)
CL (1) CL2008003391A1 (de)
DE (1) DE60335293D1 (de)
PE (1) PE20040168A1 (de)
PL (1) PL374759A1 (de)
TW (1) TW200403245A (de)
WO (1) WO2003082208A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2273083C (en) * 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
EP2186811A1 (de) * 2002-08-23 2010-05-19 Sloan-Kettering Institute For Cancer Research Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
DK1581535T5 (da) * 2003-01-09 2009-12-21 Astellas Pharma Inc Pyrrolopyridazinderivater
US7030112B2 (en) * 2003-03-25 2006-04-18 Bristol-Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7432373B2 (en) * 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
WO2006004191A1 (en) * 2004-07-05 2006-01-12 Astellas Pharma Inc. Pyrrolopyridazine derivatives which inhibit pde iv and tnf alfa
US7880004B2 (en) 2005-09-15 2011-02-01 Bristol-Myers Squibb Company Met kinase inhibitors
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
AR057986A1 (es) * 2005-11-21 2008-01-09 Japan Tobacco Inc Compuesto heterociclico y su uso farmaceutico
HRP20150642T1 (hr) * 2006-12-22 2015-08-14 Astex Therapeutics Limited BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a
US8513276B2 (en) 2006-12-22 2013-08-20 Astex Therapeutics Limited Imidazo[1,2-a]pyridine compounds for use in treating cancer
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
CA2716856C (en) 2008-03-20 2013-02-19 Amgen Inc. Aurora kinase modulators and method of use
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
ES2599458T3 (es) * 2008-10-14 2017-02-01 Sunshine Lake Pharma Co., Ltd. Compuestos y métodos de uso
EP2408300B1 (de) * 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Aminoesterderivate, salze daraus und verfahren zu ihrer verwendung
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
AR077428A1 (es) * 2009-07-29 2011-08-24 Sanofi Aventis (aza) indolizinacarboxamidas ciclicas su preparacion y su uso como agentes farmaceuticos
TW201107330A (en) * 2009-07-31 2011-03-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
JP6386527B2 (ja) * 2013-03-11 2018-09-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ カリウムイオンチャネル阻害剤としてのピロロピリダジン
BR112020006677A2 (pt) 2017-10-05 2020-10-06 Fulcrum Therapeutics, Inc. uso de inibidores p38 para reduzir a expressão de dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
EP3710005B8 (de) * 2017-11-17 2023-06-14 Academia Sinica SUBSTITUIERTE PYRROLO[2,1,-ALPHA]PHTHALAZINE- UND BENZO[g]PYRROL[2,1,-ALPHA]PHTHALAZINEDERIVATE UND IHRE VERWENDUNG ZUR BEHANDLUNG VON KREBS
US12269822B2 (en) 2018-07-09 2025-04-08 Boehringer Ingelheim Animal Health USA Inc. Anthelminthic heterocyclic compounds
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
MX2021011302A (es) 2019-03-19 2022-01-19 Boehringer Ingelheim Animal Health Usa Inc Compuestos de aza-benzotiofeno y aza-benzofurano como antihelminticos.
KR20230028268A (ko) 2020-05-29 2023-02-28 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 구충성 헤테로시클릭 화합물
US11999742B2 (en) 2021-11-01 2024-06-04 Boehringer Ingelheim Vetmedica Gmbh Substituted pyrrolo[1,2-b]pyridazines as anthelmintics
WO2026019977A1 (en) * 2024-07-19 2026-01-22 Merck Sharp & Dohme Llc Pyrrolopyridazine vegfr inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1302300A (zh) 1998-05-21 2001-07-04 盐野义制药株式会社 吡咯并[1,2－b]哒嗪sPLA2抑制剂
MXPA01002173A (es) 1998-08-28 2003-07-14 Scios Inc Inhibidores de p38-alfa cinasa.
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
JP4649046B2 (ja) 1999-05-21 2011-03-09 ブリストル−マイヤーズ スクイブ カンパニー キナーゼのピロロトリアジン阻害剤
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
AU2001267823A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
GEP20063915B (en) 2000-11-17 2006-09-11 Bristol Myers Squibb Co PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors

Also Published As

Publication number Publication date
WO2003082208A2 (en) 2003-10-09
AU2003223380A8 (en) 2003-10-13
EP1578351B1 (de) 2010-12-08
WO2003082208A8 (en) 2005-03-24
TW200403245A (en) 2004-03-01
PL374759A1 (en) 2005-10-31
AR039189A1 (es) 2005-02-09
AU2003223380A1 (en) 2003-10-13
WO2003082208A3 (en) 2006-03-02
DE60335293D1 (de) 2011-01-20
US6900208B2 (en) 2005-05-31
US20040063712A1 (en) 2004-04-01
JP4589005B2 (ja) 2010-12-01
JP2006504624A (ja) 2006-02-09
EP1578351A2 (de) 2005-09-28
CL2008003391A1 (es) 2009-03-06
EP1578351A4 (de) 2006-06-14
PE20040168A1 (es) 2004-03-27
US20050159420A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
ATE490964T1 (de) Pyrrolopyridazin-verbindungen und verwendungsverfahren dafür zur behandlung von proliferativen erkrankungen
EP1701664A4 (de) System und verfahren zur behandlung von gewebe
DE60227095D1 (de) Zusammensetzungen und verfahren zur behandlung von abgebundenem gips
DE60313297D1 (de) Gerät zum nachweis und zur behandlung von synkope
ATE369133T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
DE60039415D1 (de) Reovirus zur behandlung von zellulären proliferativen erkrankungen
DE602004010419D1 (de) Triazaspiropiperidinderivate zur verwendung als glyt-1-inhibitoren bei der behandlung von neurologischen und neuropsychiatrischen erkrankungen
EP1626730A4 (de) Verfahren, gerät und zusammensetzung zur behandlung von akne
EP1469871A4 (de) Verfahren zur behandlung von apoptose und zusammensetzungen dafür
ATE468331T1 (de) Neue cyanopyridine-derivate zur behandlung von krebs und anderer erkrankungen
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
DE602004022061D1 (de) Verwendung von modifizierten cyclosporinen zur behandlung von hcv-erkrankungen
DE602006018583D1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
ATE389649T1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
ATE462708T1 (de) Zur behandlung von hyperproliferationserkrankungen und mit angiogenese assoziierten krankheiten geeignete pyrrolotriazinderivate
EP1664051A4 (de) Pyrrolopyridazin-verbindungen und verwendungsverfahren zur behandlung von proliferativen erkrankungen
DE60214542D1 (de) Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
EP1635801A4 (de) Verfahren zur behandlung und prävention von herzarrhythmie
DE602004026405D1 (de) Formulierung und verfahren zur behandlung von thrombocythämie
DE602004001134D1 (de) Tetrazolderivate und verfahren zur behandlung von stoffwechselbedingten erkrankungen damit
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
DE60136748D1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
ATE423099T1 (de) Zur behandlung von schmerzen geeignete piperazine
DE60327856D1 (de) Zusammensetzungen und verfahren zur hautbräunung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties